Expedite COVID-19 Vaccine Studies Without Compromising
COVID-19 has disrupted and transformed how vaccines are developed and delivered. Signant Health’s end-to-end clinical research solutions and scientific expertise deliver high-quality safety and efficacy data quickly and at-scale while reducing burdens on participants, sites, and sponsors.
We Have Solutions to Help Your Study Succeed
Expedited clinical research, uncompromised data quality
Take advantage of Signant’s experience with large-scale, multiphase, rapid COVID-19 vaccine studies. We leverage industry-pioneering evidence generation software solutions and internal clinical science, medicine, and global operational expertise to accelerate vaccine research without sacrificing data accuracy and reliability.
Efficiency and accuracy at scale
COVID-19 vaccine studies require substantial participant populations, imposing numerous logistical complexities on sites. Signant SmartSignals eCOA, RTSM, and other study management solutions, supported by clinical and operational expertise, have been proven to help sites operate efficiently while improving data integrity in these large-scale, global vaccine studies.
Seize the data
Access your study data when and how you need it. With our data management services, you can collect, review, clean, and migrate clinical data as your protocol requires. From audit trail logs to change authorizations and database locks/archiving, our systems and services also facilitate seamlessly moving between study phases following adaptive design decision points.
Collect long-term efficacy and safety data in post-marketing
Our secure and compliant Telemedicine solution replaces on-site visits with convenient video consultations, making it possible to reach a wider, more diverse patient population. The virtual platform allows study teams to frequently check in and communicate with patients.
COVID-19 has ushered in a new era of multi-modal clinical research. Whether your protocol requires in-person, virtual, or hybrid modes of conduct, Signant has the tools, flexibility, global reach, and clinical science expertise to bring trials to your participants.
Standard on-site, virtual, or hybrid - any trial model
Participant safety is paramount
Mitigate risks to participants and study teams – our Signant SmartSignals eCOA solution reduces site visits and simplifies collection of primary safety data, while our Randomization and Trial Supply Management (RTSM) allows modifications study supply and distribution schemes to promote your primary endpoint and concern & safety.
40+
LANGUAGES
COUNTRIES
30+
140,000+
PATIENTS
3,500+
SITES
STUDIES
95+
II-IV
PHASES
Our Vaccine Experience
70+
20+
BYOD
PROVISIONED
MODALITY
COVID-19 Vaccine Trials Overview
COVID-19 Vaccine Resources
Signant's Subject Matter Experts
Enhance Your COVID-19 Vaccine Solutions with Signant
BLINDED DATA ANALYTICS
RTSM
eCOA
eCONSENT
LEARN MORE 🠖LEARN MORE 🠖LEARN MORE 🠖LEARN MORE 🠖
